CaseyGerry: Leadership in Drug Litigation

Partner Frederick Schenk concentrates his practice on serious personal injury and products liability, including pharmaceutical litigation. Schenk, who has been with CaseyGerry for 38 years and in practice for 42 years, has been twice recognized by Best Lawyers as San Diego’s Trial Lawyer of the Year in the area of mass torts and class action litigation in 2014 and 2018. Other awards include being recognized as one of 50 Influential Leaders in San Diego for 2019, Lawdragon’s “500 Leading Plaintiff Consumer Lawyers” for 2019, one of the Best Lawyers in America in its 2020 Edition, and an Outstanding Trial Lawyer by the Consumer Attorneys of San Diego. Schenk is currently serving as president of the San Diego Chapter of the American Board of Trial Advocates.

Schenk has tremendous experience prosecuting cases on behalf of injured individuals in mass tort litigation, including In Re: National Football League Players’ Concussion Injury Litigation, Multidistrict Litigation (MDL) No. 2323, where Schenk was appointed by U.S. District Court Judge Anita B. Brody to serve on the Plaintiffs Steering Committee.

Schenk has also led CaseyGerry’s mesothelioma and asbestos practice team and obtained the largest verdict ever in San Diego against an asbestos manufacturer, totaling $2.4 million in both economic and punitive damages.

Currently, Schenk is actively involved in representing clients injured by Zantac and generic ranitidine in the MDL In Re: Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924, currently pending in United States District Court, Southern District of Florida.

Elmiron (pentosan polysulfate sodium)

The CaseyGerry law firm is representing individuals who have developed pigmentary maculopathy as a result of taking the drug Elmiron.

Recently, studies have found a link between chronic exposure to Elmiron (pentosan polysulfate sodium) and pigmentary maculopathy, a disease that is unique to Elmiron exposure. Symptoms of pigmentary maculopathy include dim vision, difficulty reading, difficulty adjusting to the dark or low lighting and areas of vision loss. In some cases, vision loss is permanent.

If you have taken Elmiron and either have been diagnosed with pigmentary maculopathy or have experienced symptoms associated with maculopathy, you may be eligible for compensation. For a free consultation, please complete the Elmiron Litigation Questionnaire or call CaseyGerry at (619) 238-1811.